STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13D/A] abrdn Life Sciences Investors SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Saba Capital Management, L.P., Saba Capital Management GP, LLC and Boaz R. Weinstein filed Amendment No. 9 to Schedule 13D reporting beneficial ownership of 2,274,356 common shares of abrdn Life Sciences Investors (HQL), equal to 7.88% of the outstanding shares based on 28,872,416 shares outstanding as of 3/31/25. The event triggering this filing occurred on 11/21/2025.

All reporting persons share voting and dispositive power over these shares and have no sole voting or dispositive authority. Approximately $29,826,505 was paid to acquire the reported position, using investor subscription proceeds, capital appreciation, and ordinary-course margin borrowings. Funds and accounts advised by Saba Capital are entitled to dividends and sale proceeds. This amendment updates Items 3, 5 and 7, and lists Schedule A as an exhibit detailing recent open-market transactions.

Positive

  • None.

Negative

  • None.





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 28,872,416 shares of common stock outstanding as of 3/31/25, as disclosed in the company's N-CSRS filed 6/9/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 28,872,416 shares of common stock outstanding as of 3/31/25, as disclosed in the company's N-CSRS filed 6/9/25.


SCHEDULE 13D




Comment for Type of Reporting Person:
The percentages used herein are calculated based upon 28,872,416 shares of common stock outstanding as of 3/31/25, as disclosed in the company's N-CSRS filed 6/9/25.


SCHEDULE 13D


Saba Capital Management, L.P.
Signature:/s/ Michael D'Angelo
Name/Title:General Counsel
Date:11/24/2025
Boaz R. Weinstein
Signature:/s/ Michael D'Angelo
Name/Title:Authorized Signatory
Date:11/24/2025
Saba Capital Management GP, LLC
Signature:/s/ Michael D'Angelo
Name/Title:Attorney-in-fact*
Date:11/24/2025
Comments accompanying signature:
Pursuant to a power of attorney dated as of November 16, 2015, which is incorporated herein by reference to Exhibit 2 to the Schedule 13G filed by the Reporting Persons on December 28, 2015, accession number: 0001062993-15-006823

FAQ

What stake in HQL does Saba Capital report in this Schedule 13D/A?

The filing reports that the Saba Capital reporting group beneficially owns 2,274,356 HQL common shares, representing 7.88% of the outstanding shares based on 28,872,416 shares as of 3/31/25.

Who are the reporting persons in the HQL Schedule 13D/A Amendment No. 9?

The reporting persons are Saba Capital Management, L.P., Saba Capital Management GP, LLC, and Boaz R. Weinstein, who report shared voting and dispositive power over the 2,274,356 HQL common shares.

How much did Saba Capital pay to acquire its HQL position?

The filing states that approximately $29,826,505 was paid to acquire the HQL common shares reported as beneficially owned.

How was the HQL investment by Saba Capital funded?

Funds for purchasing HQL common shares came from subscription proceeds from investors, capital appreciation, and margin account borrowings made in the ordinary course of business.

What is the date of the event requiring this HQL Schedule 13D/A filing?

The event that required this Schedule 13D/A Amendment No. 9 was dated 11/21/2025, as shown on the cover page.

Which items are amended in this HQL Schedule 13D/A Amendment No. 9?

The document states that Amendment No. 9 amends Items 3, 5, and 7, including the source of funds, interest in HQL securities, and the exhibit list.

Who receives dividends and sale proceeds from the HQL shares reported?

The filing states that the funds and accounts advised by Saba Capital have the right to receive dividends and proceeds of sales from the HQL common shares.
abrdn Life Sciences Investors

NYSE:HQL

HQL Rankings

HQL Latest News

HQL Latest SEC Filings

HQL Stock Data

485.35M
28.87M
0.01%
32.27%
0.27%
Asset Management
Financial Services
Link
United States
Philadelphia